Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection.
Gilad
J
J
Infectious Disease Institute, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Borer
A
A
Hallel-Halevy
D
D
Riesenberg
K
K
Alkan
M
M
Schlaeffer
F
F
D000328:Adult; D000967:Antimony Sodium Gluconate / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000276:immunology; D008297:Male
D000981:Antiprotozoal Agents; D000967:Antimony Sodium Gluconate